Indian Govt Move To Scrutinize MNC Investments In Indian Firms Could have "Chilling" Effect
This article was originally published in PharmAsia News
MUMBAI - The Indian government has decided to route all foreign direct investments in existing Indian companies via the Foreign Investment Promotion Board, a surprising move that could have far-reaching implications on big ticket M&As in the country's pharmaceutical industry
You may also be interested in...
Deal makers are cautiously viewing the fallout of a recent government statute to prevent non-compete clauses in cross-border deals for existing Indian companies except in special circumstances. Experts await clarification on the statute but some say the new norm will impede deals and affect valuations.
A truce between government departments was reached on the issue of foreign direct investments in the pharmaceutical industry. In the new setting, the “non-compete” clause will be removed lending flexibility to the seller to start up a competing enterprise.
A proposal by an Indian government department may make buy-outs of existing local drug units difficult for global companies. The new provisions include removal of a non-compete clause and several other pre-conditions for the buyer.